

Form PTO-1449 (modified)

Atty. Docket No.

CLFR:029USD1

Serial No.

10/676,725

List of Patents and Publications for Applicant's

Applicant

Michael Rosenblum

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

October 1, 2003

Group:

1615

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 4



U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<input checked="" type="checkbox"/>	A8	2004/0013691	1/22/04	Rosenblum	424	234.1	6/12/03
<input checked="" type="checkbox"/>	A9	4,263,279	4/21/81	Sela <i>et al.</i>	424	85	7/24/78
<input checked="" type="checkbox"/>	A10	4,414,148	11/8/83	Jansen <i>et al.</i>	530	391.9	4/14/82
<input checked="" type="checkbox"/>	A11	4,522,918	6/11/85	Schlom <i>et al.</i>	435	68	12/15/81
<input checked="" type="checkbox"/>	A12	4,590,071	5/20/86	Scannon <i>et al.</i>	424	85	11/25/84
<input checked="" type="checkbox"/>	A13	4,677,064	6/30/87	Mark <i>et al.</i>	435	68	5/2/85
<input checked="" type="checkbox"/>	A14	4,801,578	6/4/84	Monsigny <i>et al.</i>	514	8	6/4/84
<input checked="" type="checkbox"/>	A15	4,831,122	5/16/89	Buchsbaum <i>et al.</i>	530	391.3	1/9/86
<input checked="" type="checkbox"/>	A16	4,863,726	11/5/89	Stevens <i>et al.</i>	424	85.2	12/9/87
<input checked="" type="checkbox"/>	A17	4,888,415	12/19/89	Lambert <i>et al.</i>	530	390	3/7/88
<input checked="" type="checkbox"/>	A18	4,894,225	1/16/90	Zimmerman	424	85.1	3/2/87
<input checked="" type="checkbox"/>	A19	4,894,227	1/16/90	Stevens <i>et al.</i>	424	85.2	5/29/87
<input checked="" type="checkbox"/>	A20	4,894,443	1/16/90	Greenfield <i>et al.</i>	530	388	11/7/84
<input checked="" type="checkbox"/>	A21	4,946,778	8/7/90	Landner <i>et al.</i>	435	69.6	1/19/89
<input checked="" type="checkbox"/>	A22	4,962,188	10/9/90	Frankel	530	389	9/30/86
<input checked="" type="checkbox"/>	A23	4,963,354	10/16/90	Shepard <i>et al.</i>	424	85.1	1/21/87
<input checked="" type="checkbox"/>	A24	4,980,457	12/25/90	Jansen <i>et al.</i>	530	391	11/11/87
<input checked="" type="checkbox"/>	A25	5,017,371	5/21/91	Cummins	424	85.6	1/6/88
<input checked="" type="checkbox"/>	A26	5,019,368	5/28/91	Epstein <i>et al.</i>	424	1.1	2/23/89
<input checked="" type="checkbox"/>	A27	5,134,075	7/28/92	Hellstrom <i>et al.</i>	530	387.3	2/17/89
<input checked="" type="checkbox"/>	A28	5,359,046	10/25/94	Capon <i>et al.</i>	536	23.4	12/9/92
<input checked="" type="checkbox"/>	A29	5,624,827	4/29/97	Rosenblum and Beattie	435	91.5	10/21/94
<input checked="" type="checkbox"/>	A30	5,631,348	5/20/97	Rosenblum <i>et al.</i>	530	370	6/06/94

25527756.1

EXAMINER:

DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A31	5,720,954	2/24/98	Hudziak <i>et al.</i>	424	130.1	5/23/95
	A32	5,744,580	4/28/98	Better <i>et al.</i>	530	377	6/7/95
	A33	5,770,195	6/23/98	Hudziak <i>et al.</i>	424	130.1	5/23/95
	A34	5,837,491	11/17/98	Better <i>et al.</i>	435	69.1	5/12/94
	A35	6,084,073	7/4/00	Piatak, Jr.	530	370	6/5/95
	A36	6,099,842	8/8/00	Pastan <i>et al.</i>	424	183.1	12/3/90
	A37	6,214,974	4/10/01	Rosenblum and Donato	530	391.9	3/27/95
	A38	6,306,626	10/23/01	Rosenblum and Donato	435	70.21	2/07/94
	A39	6,599,505	7/29/03	Rosenblum	424	134.1	2/19/98
	A40	6,669,938	12/30/03	Rosenblum <i>et al.</i>	424	183.1	11/24/93
	A41	6,750,329	6/15/04	Rosenblum <i>et al.</i>	530	391.7	5/31/94
	A42	RE37,642	12/04/01	Rosenblum <i>et al.</i>	530	370	5/20/99
	A43	10/926,731		Rosenblum			8/26/04
	A44	2003/0073163	4/17/03	Fernandez <i>et al.</i>	435	69.1	11/14/01
	A45	2003/0086919	5/08/03	Rosenblum and Liu	424	94.63	7/17/02
	A46	2003/0134302	7/17/03	Fernandez <i>et al.</i>	435	6	8/01/02
	A47	2003/0176331	9/18/03	Rosenblum and Cheung	514	12	2/12/02
	A48	2003/0186384	10/02/03	Barth <i>et al.</i>	435	69.5	4/20/01
	A49	2004/0009477	1/15/04	Fernandez <i>et al.</i>	435	6	11/21/01

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B8	EP 0160446	4/15/85	Europe			English

25527756.1



EXAMINER:

DATE CONSIDERED: 8/24/08

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B9	EP 0222360	5/20/87	Europe			English
	B10	EP 0305967	3/8/89	Europe			None
	B11	EP 0336631	10/11/89	Europe			English
	B12	EP 0350230	1/10/90	Europe			English
	B13	EP 0396387	11/7/90	Europe			English
	B14	GB 2148299	5/30/85	United Kingdom			English
	B15	JP 190200	8/20/87	Japan			Partial
	B16	JP 62209098	12/6/86	Japan			Abstract
	B17	JP 86121	7/13/81	Japan			Partial
	B18	WO 85/00974	8/31/84	WIPO			English
	B19	WO 86/02945	5/22/86	WIPO			English
	B20	WO 86/05098	7/8/85	WIPO			English
	B21	WO 87/00056	6/6/86	WIPO			English
	B22	WO 88/09343	12/1/88	WIPO			Abstract
	B23	WO 89/00999	2/9/89	PCT			English
	B24	WO 90/00405	1/25/90	WIPO			English
	B25	WO 91/16071	10/31/91	WIPO			English
	B26	WO 94/26910	11/24/94	WIPO			English
	B27	WO 97/22364	6/26/97	WIPO			English
	B28	WO 97/46259	12/11/97	WIPO			English
	B29	WO 99/49059	9/30/99	WIPO			English
	B30	WO 99/40198	8/12/99	WIPO			English
	B31	WO 99/45128	9/10/99	WIPO			English

25527756.1

EXAMINER:



DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.



INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B32	WO 99/51620	10/14/99	WIPO			English
	B33	WO 99/51766	10/14/99	WIPO			English
	B34	WO 03/002598	1/09/03	WIPO			English
	B35	WO 00/34317	6/15/00	WIPO			English
	B36	AU A13017/88	9/15/88	Australia			English
	B37	AU A21725/88	3/23/89	Australia			English
	B38	AU A30753/89	8/31/89	Australia			English
	B39	AU B79527/87	4/14/88	Australia			English
	B40	AU B82047/87	6/9/88	Australia			English
	B41	EP 0118365	3/2/84	Europe			English
	B42	EP 0150126	7/31/85	Europe			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C18	Blink <i>et al.</i> , "Curtin Conference: Perforin-dependent nuclear targeting of granzymes: A central role in the nuclear events of granule-exocytosis-mediated apoptosis?," <i>Immunology and Cell Biology</i> , 77:206-215, 1999.
	C19	Bolognesi <i>et al.</i> , "In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins," <i>Br. J. Haematol.</i> , 110(2):351-361, 2000.
	C20	Brunet <i>et al.</i> , "The inducible cytotoxic T-lymphocyte-associated gene transcript CTLA-1 sequence and gene localization to mouse chromosome 14," <i>Nature</i> , 322(6076):268-271, 1986.
	C21	Bumol <i>et al.</i> , "Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans," <i>J. Biol. Chem.</i> , 259:12733-12741, 1984.

25527756.1

EXAMINER:



DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C22	Chan <i>et al.</i> , "Comparison of gallium-67 versus indium-111 monoclonal antibody (96.5, ZME-018) in detection of human melanoma in athymic mice," <i>J. Nucl. Med.</i> , 28:1441-1446, 1987.
	C23	Chaudhary <i>et al.</i> , "A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin," <i>Nature</i> , 339:394-397, 1989.
	C24	Collen <i>et al.</i> , "Recombinant staphylokinase variants with altered immunoreactivity," <i>Circulation</i> , 94:197-206, 1996.
	C25	Crosby <i>et al.</i> , "A complex of serine protease gene expressed preferentially in cytotoxic T-lymphocytes is closely linked to the T-cell receptor alpha- and delta-chain genes on mouse chromosome 14," <i>Genomics</i> , 6(2):252-259, 1990.
	C26	Dahl <i>et al.</i> , "Isolation of a cDNA clone encoding a novel form of granzyme B from human NK cells and mapping to chromosome 14," <i>Hum. Genet.</i> , 84(5):465-470, 1990.
	C27	DeLand <i>et al.</i> , "A perspective of monoclonal antibodies: past, present, and future," <i>Seminars in Nuc. Med.</i> , 19(3):158-165.
	C28	Dermer, "Another anniversary for the war on cancer," <i>Bio/technology</i> , 12:320, 1994.
	C29	Dillman, "Monoclonal antibodies for treating cancer," <i>Ann. Intern. Med.</i> , 111:592-603, 1989.
	C30	Dumontet, "[Immunotherapy and cancer: the role of monoclonal antibodies]," <i>J. Chir. (Paris)</i> , 126:682-686, 1989.
	C31	Engert <i>et al.</i> , "Resistance of myeloid leukaemia cell lines to ricin A-chain immunotoxins," <i>Leuk. Res.</i> , 15:1079-1086, 1991.
	C32	Falasca <i>et al.</i> , "Properties of the ribosome-inactivating proteins gelonin, Momordica charantia inhibitor, and dianthins," <i>Biochem. J.</i> , 207:505-509, 1982.
	C33	Fiers <i>et al.</i> , "Tumor necrosis factor: a potential anti tumor agent," <i>J. Interferon Res.</i> , 7:627-634, 1987.
	C34	Frankel <i>et al.</i> , "Prospects for immunotoxin therapy in cancer," <i>Ann. Rev. Med.</i> , 37:125-142, 1986.
	C35	Freshney, "Culture of animal cells, a manual of basic technique," Alan R. Liss, Inc, 1983.
	C36	Friedman <i>et al.</i> , "BR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cells," <i>Cancer Res.</i> , 53:334-339, 1993.

25527756.1



EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C37	Frontiera <i>et al.</i> , "Sequential use of indium-111 labeled monoclonal antibodies 96.5 and ZME-018 does not increase detection sensitivity for metastatic melanoma," <i>Clin. Nucl. Med.</i> , 14:357-366, 1989.
	C38	Gallego <i>et al.</i> , "Preparation of four daunomycin-monoclonal antibody 791T/36 conjugates with anti-tumour activity," <i>Int. J. Cancer</i> , 33:737-744, 1984.
	C39	Gase <i>et al.</i> , "Functional significance of NH ₂ - and COOH- terminal regions of staphylokinase in plasminogen activation," <i>Thrombosis and Haemostasis</i> , 76(5):755-760, 1996.
	C40	GenBank Accession Number L12243.
	C41	Giacomini <i>et al.</i> , "Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells," <i>J. Immunol.</i> , 133(3):1649-1655, 1984.
	C42	Gillies <i>et al.</i> , "Antigen binding and biological activities of engineered mutant chimeric antibodies with human tumor specificities," <i>Hum. Antibodies Hybridomas.</i> , 1:47-54, 1990.
	C43	Gould <i>et al.</i> , "Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies," <i>J. Natl. Cancer Inst.</i> , 81:775-781, 1989.
	C44	Green <i>et al.</i> , "Monoclonal antibody therapy for solid tumors," <i>Cancer Treat Rev.</i> , 26:269-286, 2000.
	C45	Greiner <i>et al.</i> , "Differential effects of recombinant human leukocyte interferons on cell surface antigen expression," <i>Cancer Res.</i> , 46:4984-4990, 1986.
	C46	Greiner <i>et al.</i> , "Enhanced expression of surface tumor-associated antigens on human breast and colon tumor cells after recombinant human leukocyte alpha-interferon treatment," <i>Cancer Res.</i> , 44:3208-3214, 1984.
	C47	Haddad <i>et al.</i> , "Structural organization of the hCTLA-1 gene encoding human granzyme B," <i>Gene</i> , 87(2):265-271, 1990.
	C48	Hamburger and Salmon, "Primary bioassay of human tumor stem cells," <i>Science</i> , 197:461-463, 1977.
	C49	Hann <i>et al.</i> , "Building 'validated' mouse models of human cancer," <i>Curr. Opin. Cell Biol.</i> , 13:778-784, 2001.

25527756.1

EXAMINER:

DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C50	Hanson <i>et al.</i> , "A cluster of hematopoietic serine protease genes is found on the same chromosomal band as the human $\alpha\delta$ T-cell receptor locus," <i>Proc. Natl. Acad. Sci., USA</i> , 87:960-963, 1990.
	C51	Harlow <i>et al.</i> , <i>Antibodies: A laboratory Manual</i> , Cold Spring Harbor Press, pp. 72-77, 92-97, 128-135, and 141-157, 1988.
	C52	Harper <i>et al.</i> , "Proximity of the CTLA-1 serine esterase and Tcr alpha loci in mouse and man," <i>Immunogenetics</i> , 28(6):439-444, 1988.
	C53	Henkart, "Mechanism of Lymphocyte-mediated Cytotoxicity," <i>Ann. Rev. Immunol.</i> , 3:31-58, 1985.
	C54	Hertler <i>et al.</i> , "A phase I study of T101-ricin A chain immunotoxin in refractory chronic lymphocytic leukemia," <i>J. Biol. Response Mod.</i> , 7:97-113, 1987.
	C55	Hoogenboom <i>et al.</i> , "Targeting of tumor necrosis factor to tumor cells: secretion by myeloma cells of a genetically engineered antibody-tumor necrosis factor hybrid molecule," <i>Biochim Biophys Acta.</i> , 1096:345-354, 1991.
	C56	Huston <i>et al.</i> , "Single-chain immunotechnology of Fv analogues and fusion proteins," in <i>Immunotechnology</i> , Gosling and Reen (eds), pg. 47-60, 1993.
	C57	Imai <i>et al.</i> , "[Current status of monoclonal antibodies to human melanoma and its application]," <i>Gan To Kagaku Ryoho.</i> , 10:852-860, 1983 (abstract in English).
	C58	Imai <i>et al.</i> , "Differential effect of interferon on the expression of tumor-associated antigens and histocompatibility antigens on human melanoma cells: relationship to susceptibility to immune lysis mediated by monoclonal antibodies," <i>J. Immunol.</i> , 127(2):505-509, 1981.
	C59	Johnson, "Review: Noncaspase proteases in apoptosis," <i>Leukemia</i> , 14:1695-1703, 2000.
	C60	Juhl <i>et al.</i> , "New approaches in gastric cancer research: I. Monoclonal antibodies in diagnosis and therapy," <i>Hepatogastroenterol.</i> 36:27-32, 1989.
	C61	Julius <i>et al.</i> , "Induction of resting B cells to DNA synthesis by soluble monoclonal anti-immunoglobulin," <i>Eur. J. Immunol.</i> , 14:753-757, 1984.
	C62	Kagawa <i>et al.</i> , "A binary adenoviral vector system for expressing high levels of the proapoptotic gene bax," <i>Gene Therapy</i> , 7:75-79, 2000.

25527756.1

EXAMINER:



DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C63	Kagawa <i>et al.</i> , "Antitumor Effect of Adenovirus-mediated Bax Gene Transfer on p53-sensitive and p53-resistant Cancer Lines," <i>Cancer Research</i> , 60:1157-1161, 2000.
	C64	Kam <i>et al.</i> , "Review: Granzymes (lymphocyte serine proteases): characterization with natural and synthetic substrates and inhibitors," <i>Biochimica et Biophysica Acta</i> , 1477:307-323, 2000.
	C65	Kaneta <i>et al.</i> , "Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo," <i>Jpn J. Cancer Res.</i> , 89(5):583-588, 1998.
	C66	Kim and Weaver, "Construction of a recombinant expression plasmid encoding a staphylococcal protein A-ricin A fusion protein," <i>Gene</i> , 68:315-321, 1988.
	C67	Kimmel <i>et al.</i> , "In vitro drug sensitivity testing in human gliomas," <i>J. Neurosurg.</i> 66:161-171, 1987.
	C68	Kipriyanov <i>et al.</i> , "Recombinant single-chain Fv fragments carrying c-terminal cysteine residues: production of bivalent and biotinylated miniantibodies," <i>Molecular Immunology</i> , 31:1047-1058, 1994.
	C69	Kirkwood <i>et al.</i> , "Scintigraphic detection of metastatic melanoma using indium 111/DTPA conjugated anti-gp240 antibody (ZME-018)," <i>J. Clin. Oncol.</i> , 5:1247-1255, 1987.
	C70	Klein <i>et al.</i> , "Genomic organization and chromosomal assignment for a serine protease gene (CSPB) expressed by human cytotoxic lymphocytes," <i>Genomics</i> , 5(1):110-117, 1989.
	C71	Koizumi <i>et al.</i> , "Immunoscintigraphy and pharmacokinetics of indium-111-labeled ZME-018 monoclonal antibody in patients with malignant melanoma," <i>Japanese J of Cancer Res</i> , 79:973-981, 1988.
	C72	Kovarik <i>et al.</i> , "Biochemical and histochemical characteristic of target antigen detected by monoclonal antibody HBCa-12 against a membrane component of human mammary carcinoma cell line," <i>Neoplasma</i> , 31(6):625-630, 1984.
	C73	Kudlicki <i>et al.</i> , "Elongation and folding of nascent ricin chains as peptidyl-rRNA on ribosomes: the effect of amino acid deletions on these processes," <i>J. Mol. Biol.</i> , 252:203-212, 1995.
	C74	Kufe <i>et al.</i> , "Differential reactivity of a novel monoclonal antibody (DF3) with human malignant vs. benign breast tumors," <i>Hybridoma</i> , 3(3):223-232, 1984.

25527756.1

EXAMINER:



DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)


Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C75	Kung et al., "A mouse IgM allotypic determinant (Igh-6.5) recognized by a monoclonal rat antibody," <i>J. Immunol.</i> 127:873-876, 1981.
	C76	Kurucz et al., "A bacterial expressed single-chain Fv construct from the 2B4 T-cell receptor," <i>Proc Natl Acad Sci USA</i> ; 90: 3830-3834, 1993.
	C77	Lambert et al., "Immunotoxins containing single chain ribosome-inactivating proteins," in <i>Immunotoxins</i> , Frankel ed., pg 175-209, 1988.
	C78	Lambert et al., "Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins," <i>J. Biol. Chem.</i> , 260(22):12035-12041, 1985.
	C79	Lazar et al., "Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities," <i>Mol. Cell. Biol.</i> , 8:1247-1252, 1988.
	C80	Leibovitz et al., "A hypo-osmotic medium to disaggregate tumor cell clumps into viable and clonogenic single cells for the human tumor stem cell clonogenic assay," <i>Int. J. Cell Cloning</i> , 1:478-485, 1983.
	C81	Levy et al., "Retroviral transfer and expression of a humanized, red-shifted green fluorescent protein gene into human tumor cells," <i>Nat. Biotechnol.</i> , 14:610-614, 1996.
	C82	Lewis and Crowe, "Generation of humanized monoclonal antibodies by 'best' fit framework selection and recombinant polymerase chain reaction," <i>Year Immunol.</i> , 7:110-118, 1993.
	C83	Lin et al., "Chromosomal localization of two human serine protease genes to region 14q11.2----q12 by in situ hybridization," <i>Cytogenet Cell Genet.</i> , 53(2-3):169-171, 1990.
	C84	Lubin et al., "Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis," <i>J. Biol. Chem.</i> , 272(48):30191-30195, 1997.
	C85	Macey et al., "Uptake of Indium-111-labeled monoclonal antibody ZME-018 as a function of tumor size in a patient with melanoma," <i>Am J of Physiologic Imaging</i> ; 3:1-6, 1988.
	C86	Mazurier et al., "Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein," <i>Gene Ther.</i> , 5:556-562, 1998.

25527756.1

EXAMINER:



DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C87	McCartney <i>et al.</i> , "Engineering disulfide-linked singl-chain Fv dimers [(sFv') ₂] with improved solution and targeting properties: anti-digoxin 26-10 (sFv') ₂ and anti-c-erbB-2 741F8 (sFv') ₂ made by protein folding and bonded through C-terminal cysteinyl peptides," <i>Protein Engineering</i> ; 8:301-314, 1994.
	C88	Miescher-Granger <i>et al.</i> , "Biological activities of human recombinant interferon alpha/beta targeted by anti-Epstein-Barr virus monoclonal antibodies," <i>FEBS Lett.</i> , 179:29-33, 1985.
	C89	Mihich, "Future perspectives for biological response modifiers: a viewpoint," <i>Sem Oncol.</i> , 13:234-254, 1986.
	C90	Montanaro <i>et al.</i> , "A metalloproteinase associated with gelonin, a ribosome inactivating protein," <i>Ital. J. Biochem.</i> , pg 1-10, 1984.
	C91	Moola <i>et al.</i> , "Erwinia chrysanthemi L-asparaginase: epitope mapping and production of antigenically modified enzymes," <i>Biochem J.</i> , 302(Pt 3):921-7, 1994.
	C92	Morris and Wool, "Determination by systematic deletion of the amino acids essential for catlysis by ricin A chain," <i>Proc. Natl. Acad. Sci. USA</i> , 89:4869-4873, 1992.
	C93	Motyka <i>et al.</i> , "Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis," <i>Cell</i> , 103(3):491-500, 2000.
	C94	Mujoo <i>et al.</i> , "Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin," <i>Cancer Immunology, Immunotherapy</i> ; 40:339-345, 1995.
	C95	Mujoo <i>et al.</i> , "Pharmacology and therapeutic studies with ZME-gelonin immunotoxin," <i>Proc. Am Assoc. Cancer Res</i> , 32:266, #1580, 1991.
	C96	Muldoon <i>et al.</i> , "Tracking and quantitation of retroviral-mediated transfer using a completely humanized, red-shifted green fluorescent protein gene," <i>Biotechniques</i> , 22:162-167, 1997.
	C97	Munishkin and Wool, "Systematic deletion analysis of ricin A-chain function," <i>J Biol. Chem.</i> , 270:30581-30587, 1995.
	C98	Murray <i>et al.</i> , "Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018" <i>J. Nuclear Med.</i> , 28:25-33, 1987.

25527756.1

EXAMINER:



DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C99	Murray <i>et al.</i> , "Differential in vitro effects of alpha recombinant interferon and gamma recombinant interferon on the expression of melanoma-associated antigens and 240 Kd on melanoma cell line Ts294," <i>AACR</i> , 27:313, 1986.
	C100	Murray <i>et al.</i> , "Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens," <i>J. Biol. Response Modifiers</i> , 7:152-161, 1988.
	C101	Nechushtan <i>et al.</i> , "Conformation of the Bax C-terminus regulates subcellular location and cell death," <i>EMBO Journal</i> , 18:2330-2341, 1999.
	C102	Nolan <i>et al.</i> , "Cloning and expression of a gene encoding gelonin, a ribosome-inactivating protein from <i>Gelonium multiflorum</i> ," <i>Gene</i> , 134:223-227, 1993.
	C103	Nuti <i>et al.</i> , "A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations," <i>Int. J. Cancer</i> , 29(5):539-546, 1982.
	C104	O'Boyle <i>et al.</i> , "Potentiation of antiproliferative effects of monoclonal antibody IYm-1 and immunoconjugate Lym-1-gelonin on human Burkitt's lymphoma cells with γ -interferon and tumor necrosis factor," <i>Journal of Immunotherapy</i> , 18:221-230, 1995.
	C105	O'Hare <i>et al.</i> , "Cytotoxicity of a recombinant ricin-A-chain fusion protein containing a proteolytically-cleavable spacer sequence," <i>FEBS Lett.</i> , 273:200-204, 1990.
	C106	Owens and Young, "The genetic engineering of monoclonal antibodies," <i>Journal of Immunological Methods</i> , 168:149-165, 1994.
	C107	Ozawa <i>et al.</i> , "Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor," <i>Int. J. Cancer</i> , 43:152-157, 1989.
	C108	Pagliaro <i>et al.</i> , "Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity," <i>Clin. Cancer Res.</i> , 4(8):1971-1976, 1998.
	C109	Pai and Pastan "Immunotoxin therapy for cancer," <i>JAMA</i> , 269:78-81, 1993.
	C110	Panchagnula <i>et al.</i> , "Monoclonal antibodies in drug targeting," <i>Journal of Clinical Pharmacy & Therapeutics</i> , 22:7-19, 1997.
	C111	Panchal, "Novel Therapeutic Strategies to Selectively Kill Cancer Cells; Biochemical Pharmacology," 55:247-252, 1998.

25527756.1

EXAMINER:



DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C112	Pastan <i>et al.</i> , "Recombinant toxins for cancer treatment," <i>Science</i> , 254:1173-1177, 1991.
	C113	Pearson <i>et al.</i> , "Enhanced therapeutic efficacy against an ovarian tumor xenograft of immunotoxins used in conjunction with recombinant alpha-interferon," <i>Cancer Res.</i> 50:6379-6388, 1990.
	C114	Peterson and Krohn, "Mapping of B cell epitopes on steroid 17 α -hydroxylase, and autoantigen in autoimmune polyglandular syndrome type I," <i>Clin. Exp. Immunol.</i> , 98:104-109, 1994.
	C115	Porter, "Human immune response to recombinant human proteins," <i>J. Pharmaceutical Sciences</i> , 90:1-11, 2001.
	C116	Pullyblank and Monson, "Monoclonal antibody treatment of colorectal cancer," <i>British Journal of Surgery</i> , 84:1511-1517, 1997.
	C117	Ramakrishnan and Houston, "Prevention of growth of leukemia cells in mice by monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors: pokeweed antiviral protein or ricin A chain," <i>Cancer Res.</i> , 44(4):1398-404, 1984.
	C118	Reimann <i>et al.</i> , "In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. IV. Cytotoxic effect of an anti-T11-gelonin immunotoxin," <i>J. Clin. Invest.</i> , 82:129-138, 1988.
	C119	Rissoan <i>et al.</i> , "Subtractive hybridization reveals the expression of immunoglobulinlike transcript 7, Eph-B1, granzyme B and 3 novel transcripts in human plasmacytoid dendritic cells," <i>Blood</i> , 100(9):3295-3303, 2002.
	C120	Roselli <i>et al.</i> , "Clinical value of radiolabeled monoclonal antibodies in the management of carcinoma patients," <i>In Vivo</i> , 7:615-622, 1993.
	C121	Rosenblum <i>et al.</i> , "Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin," <i>Cancer Chemotherapy and Pharmacology</i> , 44:343-348, 1999.
	C122	Rosenblum <i>et al.</i> , "A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin," <i>Mol. Biother.</i> 3:6-13, 1991.
	C123	Rosenblum <i>et al.</i> , "A gelonin-containing immunotoxin directed against human breast carcinoma," <i>Mol. Biother.</i> 4:122-129, 1992.

25527756.1

EXAMINER:

DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C124	Rosenblum <i>et al.</i> , "Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from <i>Gelonium multiflorum</i> ," <i>J Interferon Cytokine Res.</i> , 15(6):547-555, 1995.
	C125	Rosenblum <i>et al.</i> , "Antibody-mediated delivery of tumor necrosis factor (TNF- α)," <i>Proc. Am Cancer Res.</i> , 30:410, #1522, 1987.
	C126	Rosenblum <i>et al.</i> , "Antibody-mediated delivery of tumor necrosis factor (TNF-alpha): improvement of cytotoxicity and reduction of cellular resistance," <i>Cancer Commun.</i> 3:21-27, 1991.
	C127	Rosenblum <i>et al.</i> , "Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity," <i>Interferon Res.</i> , 10:141-151, 1990.
	C128	Rosenblum <i>et al.</i> , "Monoclonal Antibodies for delivery of cytokines," <i>Cancer Bull</i> , 46(1):34-39, 1994.
	C129	Rosenblum <i>et al.</i> , "An antimelanoma immunotoxin composed of antibody AMI-018 and the plant toxin gelonin," <i>Proc. Am. Assoc. Cancer Res. Annu. Meet.</i> , 29:427, #1700, 1988 (Abstract)
	C130	Rosenblum <i>et al.</i> , "Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in Xenograft models," <i>Clin Cancer Res</i> ; 5:865-874, 1999.
	C131	Rowlinson-Busza <i>et al.</i> , "Target delivery of biologic and other antineoplastic agents," <i>Current Opinion in Oncology</i> , 4:1142-1148, 1992.
	C132	Roy <i>et al.</i> , "Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells," <i>Blood</i> , 77:2404-2412, 1991.
	C133	Salmon and Liu "Effects of granulocyte-macrophage colony-stimulating factor on in vitro growth of human solid tumors," <i>J. Clin. Oncol.</i> , 7:1346-1350, 1989.
	C134	Salmon <i>et al.</i> , "Evaluation of an automated image analysis system for counting human tumor colonies," <i>Internat. J. Cell Cloning</i> , 2:142-160, 1984.
	C135	Salmon <i>et al.</i> , "Quantitation of differential sensativity of human-tumor stem cells to anticancer drugs," <i>New Eng. J. Med.</i> , 298:1321-1327, 1978.

25527756.1

EXAMINER:



DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C136	Schienberg <i>et al.</i> , "Monoclonal Antibody M195: A diagnostic marker for acute myelogenous leukemia," <i>Leukemia</i> , 3(6):440-445, 1989.
	C137	Scholz <i>et al.</i> , "Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts," <i>Eur. J. Cancer</i> , 26(8):901-905, 1990.
	C138	Scott <i>et al.</i> , "An immunotoxin composed of a monoclonal antitransferrin receptor antibody linked by a disulfide bond to the ribosome-inactivating protein gelonin: potent in vitro and in vivo effects against human tumors," <i>J. Natl. Cancer Inst.</i> , 79:1163-1172, 1987.
	C139	Singh <i>et al.</i> , "Hormonotoxins. Preparation and characterization of ovine luteinizing hormone-gelonin conjugate," <i>J. Biol. Chem.</i> , 264(6):3089-3095, 1989.
	C140	Sivam <i>et al.</i> , "Immunotoxins to a human melanoma-associated antigen: comparison of gelonin with ricin and other A chain conjugates," <i>Cancer Res.</i> , 47:3169-3173, 1987
	C141	Smyth <i>et al.</i> , "Granzymes: exogenous proteinases that induce target cell apoptosis," <i>Immunology Today</i> , 16(4):202 - 206, 1995.
	C142	Soule <i>et al.</i> , "Membrane 126-kilodalton phosphoglycoprotein associated with human carcinomas identified by a hybridoma antibody to mammary carcinoma cells," <i>Proc. Natl. Acad. Sci. USA</i> , 80:1332-1336, 1983.
	C143	Spitler <i>et al.</i> , "Immunotoxin therapy of malignant melanoma," <i>Med Oncol Tumor Pharmacother.</i> , 3:147-152, 1986.
	C144	Spitler <i>et al.</i> , "Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin," <i>Cancer Res.</i> , 47:1717-1723, 1987.
	C145	Spitler <i>et al.</i> , "Therapy of metastatic malignant melanoma using XomaZyme Mel, a murine monoclonal anti-melanoma ricin A chain immunotoxin," <i>Nuc. Med. And Biol.s.</i> , 16:625-627, 1989.
	C146	Stirpe <i>et al.</i> , "Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A," <i>J. Biol. Chem.</i> , 255:6947-6953, 1980.
	C147	Tai <i>et al.</i> , "In Vivo Cytotoxicity of Ovarian Cancer Cells through Tumor-selective Expression of the BAX Gene," <i>Cancer Res.</i> , 59:2121-2126, 1999.

25527756.1

EXAMINER:



DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
A	C148	Tao <i>et al.</i> , "Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region," <i>J. Immunol.</i> , 143:2595-2601, 1989.
	C149	Tedder <i>et al.</i> , "Epstein Barr virus binding induces internalization of the C3d receptor: a novel immunotoxin delivery system," <i>J. Immunol.</i> 137(4):1387-1391, 1986.
	C150	Thorpe <i>et al.</i> , "An immunotoxin composed of monoclonal anti-thy 1.1 antibody and a ribosome-inactivating protein from saponaria oddicalis: potent antitumor effects in vitro and in vivo," <i>J. Natl. Cancer Inst.</i> 75(1):151-159, 1985.
	C151	Thorpe <i>et al.</i> , "Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin," <i>Eur. J. Biochem.</i> , 116:447-454, 1981.
	C152	Thorpe <i>et al.</i> , "Monoclonal antibodies: clinical and regulatory issues," <i>Trends Biotechnol.</i> 11:40-42, 1993.
	C153	Till <i>et al.</i> , "An assay that predicts the ability of monoclonal antibodies to form potent ricin A chain-containing immunotoxins," <i>Cancer Res.</i> 48:1119-1123, 1988.
	C154	Vitetta <i>et al.</i> , "Redesigning nature's poisons to create anti-tumor reagents," <i>Science</i> , 238:1098-1104, 1987.
	C155	Von Hoff, "Human tumor cloning assays: applications in clinical oncology and new antineoplastic agent development," <i>Cancer and Metastasis Reviews</i> , 7:357-371, 1988.
	C156	Wahl <i>et al.</i> , "Experimental radioimmunotherapy," <i>Cancer</i> , 73:989-992, 1994.
	C157	Waldenamn, "Multichain interleukin-2 receptor: a target for immunotherapy in lymphoma," <i>J. Natl. Cancer Inst.</i> 81:914-923, 1989.
V	C158	Waldmann <i>et al.</i> , "Monoclonal antibodies in diagnosis and therapy," <i>Science</i> , 252:1657-1662, 1991.
	C159	Wels <i>et al.</i> , "Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor," <i>Journal of Steroid Biochemistry & Molecular Biology</i> , 43:1-7, 1992.
	C160	Williams <i>et al.</i> , "Targeting and therapy of human glioma xenografts in vivo utilizing radiolabeled antibodies," <i>Cancer Res.</i> 50:974s-979s, 1990.

25527756.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C161	Wool <i>et al.</i> , "Structure and evolution of mammalian ribosomal proteins," <i>Biochem Cell Biol.</i> , 73:933-947, 1995
	C162	Worn and Pluckthun, "Mutual stabilization of V _L and V _H in single-chain antibody fragments, investigated with mutants engineered for stability," <i>Biochemistry</i> , 37:13120-13127, 1998.
	C163	Xu <i>et al.</i> , "Antileukemic activity of recombinant humanized M195-gelonin immunotoxin in nude mice," <i>Leukemia</i> , 10:321-326, 1996.
	C164	Yeung <i>et al.</i> , "Trichosanthin, α -momorcharin and β -momorcharin: identity of aborifacient and ribosome-inactivating proteins," <i>Int. J. Pept. Protein Res.</i> , 31(3):265-8, 1988.
	C165	Yokota <i>et al.</i> , "Synergistic potentiation of in vivo antitumor activity of anti-human T-leukemia immunotoxins by recombinant alpha-interferon and daunorubicin," <i>Cancer Res.</i> , 50:32-37, 1990.
	C166	Young, "Cell-Mediated Killing: A common Mechanism?" <i>Cell</i> , 46:641-642, 1986.
	C167	Yung <i>et al.</i> , "In vitro chemosensitivity testing and its clinical application in human gliomas," <i>Neurosurg. Rev.</i> , 12:197-203, 1989.
	C168	Zuckerman <i>et al.</i> , "Preparation and biological activity of recombinant leukocyte interferon A [rIFN alpha A] conjugated to an antimelanoma murine monoclonal antibody [ZME-018]," <i>Proc. Amer. Assoc. Cancer Res.</i> , 28:384, 1987.
	C169	Aboud-Pirak <i>et al.</i> , "Cytotoxic activity of daunorubicin or vindesine conjugated to a monoclonal antibody on cultured MCF-7 breast carcinoma cells," <i>Biochem. Pharmacol.</i> , 38:641-648, 1989.
	C170	Adams <i>et al.</i> , "The Bcl-2 Protein Family: Arbiters of Cell Survival," <i>Science</i> , 281:1322-1326, 1998.
	C171	Alfthan <i>et al.</i> , "Properties of single-chain antibody containing different linker peptides," <i>Protein Engineering</i> , 8:725-731, 1995.
	C172	Alkan <i>et al.</i> , "Antiviral and antiproliferative effects of interferons delivered via monoclonal antibodies," <i>J. Interferon Res.</i> , 4(3):355-363, 1984.
	C173	Alley <i>et al.</i> , "Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay," <i>Cancer Res.</i> , 48:589-601, 1988.

25527756.1

EXAMINER:

DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 2	Other Art See Page 4	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C174	Aqeilan <i>et al.</i> , "Interleukin 2-Bax: a novel prototype of human chimeric proteins for targeted therapy," <i>FEBS Letters</i> , 457:271-276, 1999.
	C175	Arnon <i>et al.</i> , "Monoclonal antibodies for immunotargeting of drugs in cancer therapy," <i>Monoclonal Antibodies and Cancer Therapy</i> , Alan R. Liss, Inc. pp 243-256, 1985.
	C176	Atkinson <i>et al.</i> , "Conjugation of folate via gelonin carbohydrate residues retains ribosomal-activating properties of the toxin and permits targeting to folate receptor positive cells," <i>Biochem Molec. Biol.</i> , 276(30):27930-27935, 2001.
	C177	Barbieri and Stirpe, "Ribosome-inactivating proteins from plants: Properties and possible uses," <i>Cancer Surveys</i> , 1(3):489-520.
	C178	Batra <i>et al.</i> , "Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin," <i>Proc. Natl. Acad. Sci.</i> , 86:8545-8549, 1989.
	C179	Batra <i>et al.</i> , "Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv)," <i>Mol. Cell. Biol.</i> 11:2200-2205, 1991.
	C180	Bendig, "Humanization of rodent monoclonal antibodies by CDR grafting," <i>METHODS: A Companion to Methods in Enzymology</i> , 8:83-93, 1995.
	C181	Berkower, "The promise and pitfalls of monoclonal antibody therapeutics," <i>Current Opinion in Biotechnology</i> , 7:622-628, 1996.
	C182	Bird <i>et al.</i> , "Single-chain antigen-binding proteins," <i>Science</i> , 242:423-426, 1988.
	C183	Bjorn <i>et al.</i> , "Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins," <i>Cancer Res.</i> , 45:1214-1221, 1985.
	C184	Blair <i>et al.</i> , "Linkage of cytotoxic agents to immunoglobulins," <i>J. Immunol. Methods</i> , 59:129-143, 1983.
	C185	Blakey <i>et al.</i> , "Antibody toxin conjugates: a perspective," <i>Monoclonal Antibody Therapy</i> . Waldmann (ed). 45:50-90, 1988.

25527756.1

EXAMINER:

DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

CLFR:029USD1

Serial No.

10/676,725

List of Patents and Publications for Applicant's

Applicant

Michael Rosenblum

INFORMATION DISCLOSURE STATEMENT

Filing Date:

October 1, 2003

Group:

1615

(Use several sheets if necessary)

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,032,521	7/16/91	White <i>et al.</i>	530	388.85	3/23/87
	A2	4,650,674	3/17/87	Aggerwal <i>et al.</i>	424	85.5	12/03/84
	A3	4,671,958	6/09/87	Rodwell	424	130.1	
	A4	4,753,894	6/28/88	Frank <i>et al.</i>	435	7.23	1/11/85
	A5	4,771,128	9/13/88	Ferris <i>et al.</i>	530	391.7	10/10/86
	A6	4,870,163	9/26/89	Rubin <i>et al.</i>	530	413	8/29/85
	A7	4,935,233	6/19/90	Kell <i>et al.</i>	424	85.5	12/02/85

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	0184369	06/86	Europe			
	B2	0226418	12/85	Europe			
	B3	1564666	04/80	Great Britain			
	B4	EP 256714	2/24/88	Europe			
	B5	EP 281070	9/07/88	Europe			
	B6	WO 88/09344	12/01/88	PCT			
	B7	WO 89/06692	7/27/89	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Aggarwal and Kohr, <i>Methods in Enzymology</i> , 116:448-456, 1986.
	C2	Bradford, "A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding," <i>Analy. Biochem.</i> , 72:248-254, 1976.

25385564.1

EXAMINER:

Thu D. Cui

DATE CONSIDERED:

8/24/05

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)


Exam. Init.	Ref. Des.	Citation
<input checked="" type="checkbox"/>	C3	Cotton <i>et al.</i> , <i>Eur. J. Immunol.</i> , 3:135-140, 1978.
<input checked="" type="checkbox"/>	C4	Flannery <i>et al.</i> , "Immunomodulation: NK cells activated by interferon-conjugated monoclonal antibody against human osteosarcoma," <i>Exp. J. Cancer Clin. Oncol.</i> , 20(6):791-798, 1984.
<input checked="" type="checkbox"/>	C5	Neville and Youle, Monoclonal antibody-ricin or ricin A chain hybrids: kinetic analysis of cell killing for tumor therapy," <i>Immunol. Rev.</i> , 62:75-91, 1982.
<input checked="" type="checkbox"/>	C6	Pelham <i>et al.</i> , "Interferon- α conjugation to human osteogenic sarcoma monoclonal antibody 791T/36," <i>Cancer Immunol. Immunother.</i> , 15:210-216, 1983.
<input checked="" type="checkbox"/>	C7	Raso <i>et al.</i> , "Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen," <i>Cancer Res.</i> , 42:457-464, 1982.
<input checked="" type="checkbox"/>	C8	Rosenblum <i>et al.</i> , "Tumor necrosis factor: a multifaceted peptide hormone, <i>Critical Reviews in Immunology</i> , 21-44, 1989.
<input checked="" type="checkbox"/>	C9	Ross <i>et al.</i> , "Increased toxicity of diphtheria toxin for human lymphoblastoid cells following covalent linkage to anti-(human lymphocyte)globulin or its F(ab') ₂ fragment," <i>Eur. J. Biochem.</i> , 104:381-390, 1980.
<input checked="" type="checkbox"/>	C10	Schultz <i>et al.</i> , "Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo," <i>Proc. Natl. Acad. Sci., USA</i> , 80:5407-5411, 1983.
<input checked="" type="checkbox"/>	C11	Shoemaker <i>et al.</i> , "Development of human tumor cell line panels for use in disease-oriented drug screening," In: <i>Prediction of Response Cancer Therapy</i> , 265-286, 1988.
<input checked="" type="checkbox"/>	C12	Soule <i>et al.</i> , <i>JNCI</i> , 51(5):1409-141, 1978.
<input checked="" type="checkbox"/>	C13	Trowbridge and Domingo, "Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells," <i>Nature</i> , 294:171-173, 1981.
<input checked="" type="checkbox"/>	C14	Vitetta <i>et al.</i> , "Neoplastic B cells as targets for antibody-ricin A chain immunotoxins," <i>Immunol. Rev.</i> , 62:159-183, 1982.
<input checked="" type="checkbox"/>	C15	Vogel <i>et al.</i> , "In vivo studies with covalent sonjugates of cobra venom factor and monoclonal antibodies to human tumors," <i>Haematology and Blood Transfusion</i> , 29:514-517, 1989.
<input checked="" type="checkbox"/>	C16	White <i>et al.</i> , "Two monoclonal antibodies selective for human mammary carcinoma," <i>Cancer Res.</i> , 45(3):1337-1343, 1985.

25385564.1


EXAMINER: <i>R. J. [Signature]</i>	DATE CONSIDERED: 8/24/05
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	

Form PTO-1449 (modified)		Atty. Docket No. CLFR:029USD1	Serial No. 10/676,725
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant Michael Rosenblum	
		Filing Date: October 1, 2003	Group: 1615
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C17	Wilson <i>et al.</i> , "Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies," <i>Int. J. Cancer</i> , 28:293-300, 1981.

25385564.1

EXAMINER: 	DATE CONSIDERED: 8/24/05
EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.	